Welcome to our dedicated page for Imax SEC filings (Ticker: IMAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IMAX Corporation (NYSE: IMAX) files reports and disclosure documents with the U.S. Securities and Exchange Commission that provide detail on its entertainment technology business, capital structure, and material events. These SEC filings include current reports on Form 8-K, annual and quarterly reports, and other documents that describe the company’s convertible notes, credit facilities, and operating results.
Among its recent filings, IMAX has reported the entry into a Seventh Amended and Restated Credit Agreement, which increased its revolving borrowing capacity and set out leverage covenants, guarantees, and use of proceeds. The company has also filed an 8-K describing the issuance of 0.75% convertible senior notes due 2030, outlining interest terms, maturity, conversion rights, redemption conditions, and related capped call transactions intended to reduce potential dilution or offset certain cash payments upon conversion.
Investors reviewing IMAX filings can use this page to access documents that discuss the company’s financial obligations, including convertible debt, revolving credit facilities, and related covenants. Filings also reference IMAX’s global footprint, with systems operating in multiple countries and territories, and its listing on the New York Stock Exchange under the symbol IMAX.
Stock Titan’s SEC filings page for IMAX provides real-time access to new submissions from the EDGAR system, along with AI-powered summaries designed to explain the key terms and implications of complex filings. Users can quickly identify items related to financing transactions, results of operations, and other material corporate developments, and can locate information relevant to topics such as note conversion features, redemption provisions, and reporting covenants.
IMAX Corporation reported lower Q1 2026 revenue but higher earnings per share for common shareholders. Revenue was $81.4 million, down from $86.7 million a year earlier, as both Content Solutions and Technology Products and Services delivered slightly weaker sales and gross margins.
Income from operations was $10.0 million versus $16.7 million, and net income was $6.1 million compared with $8.2 million. However, net income attributable to common shareholders rose to $4.2 million from $2.3 million, with diluted EPS increasing to $0.07 from $0.04, helped by a smaller share of earnings going to non-controlling interests.
IMAX ended the quarter with $146.0 million of cash and cash equivalents and total assets of $893.2 million. It had $49.0 million drawn on its $375.0 million revolving credit facility and $250.0 million of 0.750% Convertible Senior Notes due 2030 outstanding, resulting in a Senior Secured Net Leverage Ratio of 0.02:1.00, well within covenant limits. Operating cash flow was $4.0 million, down from $7.0 million, reflecting higher working capital outflows and investment in film assets and joint revenue sharing systems.
IMAX Corporation reported mixed first-quarter 2026 results. Revenue declined 6% year-over-year to $81.4 million, with gross margin down to $45.8 million and Total Adjusted EBITDA falling 18% to $30.5 million. GAAP net income decreased 26% to $6.1 million, but net income attributable to common shareholders rose 83% to $4.2 million.
On a per-share basis, diluted EPS increased to $0.07 from $0.04, while adjusted diluted EPS grew 31% to $0.17. Global box office reached $260 million, down 13% due mainly to a tougher comparison in China, although box office outside Greater China grew 67%. IMAX reaffirmed full-year 2026 guidance for $1.4 billion in global box office and highlighted continued network expansion to 1,865 systems, system backlog of 435, and available liquidity of $528 million.
IMAX CORP Chief Executive Officer Richard Gelfond reported an option exercise and related share sale. On April 27, 2026, he converted 8,943 stock options into common shares at $31.40 per share, then sold 8,943 common shares at an average price of $37.3269 per share.
The transactions were executed pursuant to a Rule 10b5-1 plan dated December 9, 2025, and sales under that plan are now complete. Following these transactions, Gelfond holds 765,002 common shares, with remaining outstanding option, restricted share unit and common share balances of 1,332,411 stock options, 231,562 restricted share units and 765,002 common shares, respectively.
IMAX reported insider sales via a Form 144. Director Richard Gelfond reported multiple planned dispositions of Common stock by cashless exercise/same-day sale, including sales of 135,046 shares on 04/10/2026 and 121,220 shares on 03/10/2026. The filings list per-trade proceeds alongside each transaction.
IMAX Corporation is asking shareholders to vote at a virtual Annual General Meeting on June 10, 2026. Items include electing ten directors, appointing PricewaterhouseCoopers as independent auditors, and an advisory say‑on‑pay vote on executive compensation.
The company highlights a record 2025, with global box office of $1.28 billion, revenue of $410.2 million, net income of $45.5 million, and total shareholder return of over 44%. Total Adjusted EBITDA reached $184.9 million, with margins improving, and bonuses and PSUs paid above target under its pay‑for‑performance framework.
As of April 13, 2026, IMAX had 55,015,891 common shares outstanding, each carrying one vote. The Douglas Group is the largest disclosed holder, with about 15.23% of outstanding shares. The Board unanimously recommends voting FOR all three proposals.
IMAX CORP Chief Executive Officer Richard L. Gelfond exercised stock options and sold the resulting shares in pre-planned trades. On April 16–17, 2026, he converted a total of 75,919 stock options into common shares at $31.40 per share and executed open‑market sales of the same 75,919 common shares at roughly $37.05 per share, pursuant to a Rule 10b5‑1 plan dated December 9, 2025.
Following these transactions, Mr. Gelfond directly holds 765,002 common shares, with additional remaining awards of 1,341,354 outstanding stock options and 231,562 restricted share units. The options exercised were originally granted in 2016 and are scheduled to expire on June 7, 2026, so the activity reflects the use of nearing‑expiration options combined with a pre‑scheduled liquidity event.
IMAX reported that Richard Gelfond executed multiple sales of Common Stock reported on Form 144, totaling 443,159 shares. The filing lists discrete dispositions on 03/10/2026, 04/02/2026, 04/06/2026, 04/10/2026, 04/13/2026, 04/14/2026, 04/15/2026, and 04/16/2026
The listed proceeds sum to $16,979,793.05 across those transactions; the sales are shown as dispositions of shares acquired under stock options on 06/07/2016 via cashless exercise/same-day sale.
IMAX Corporation temporarily adjusted its leadership structure while CEO Richard Gelfond is on medical leave. The board appointed Robert D. Lister, currently Chief Legal Officer and Senior Executive Vice President, to serve as interim principal executive officer until May 1, 2026, when Mr. Gelfond will resume the role.
Mr. Lister will keep his existing responsibilities and will not receive any additional compensation for this interim assignment. The company states there are no special arrangements, related-party transactions, new or amended contracts, or family relationships connected to his appointment, and incorporates his biography by reference from a prior proxy statement.
Richard Gelfond reports proposed sales of Common Stock under Form 144, totaling multiple transactions in March–April 2026. The notice lists individual proposed sale quantities and gross proceeds on specific dates, including 121,220 shares for $4,860,837.15 on 03/10/2026 and 135,046 shares for $5,106,872.53 on 04/10/2026.